Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2000-09-11
2009-08-11
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S278100, C514S002600
Reexamination Certificate
active
07572436
ABSTRACT:
The invention involves cellular and biological responses to relatively low concentrations of thionin (such asPyrulariathionin), which responses are distinct from the direct cytotoxic effect of high concentrations of thionins on cells. These two separate biological responses of immune cells to thionins are related to the presence of two separate and distinct binding sites on the immune cell, a high affinity binding site that reacts with thionins at low concentrations to stimulate the immune cell to provide antitumor protection, and a low affinity site that is responsible for the direct toxicity of thionins to cells. This invention provides, in certain embodiments, methods for using a thionin, either alone or in combination with an interleukin, for stimulation of the immune system. Particular embodiments provide methods for inhibition of tumor formation and/or tumor metastasis, methods for the stimulation of natural killer cells, methods for the stimulation of T cell lymphocyte differentiation and proliferation, and/or methods for the stimulation of cytokine production by various immune cells. Also provided are compositions that include thionin, e.g.,Pyrulariathionin, for the treatment and/or prevention of neoplasia, for the treatment of viral infection, for the treatment of immune deficiency (e.g., such as is caused by disease or advancing age). Other embodiments of the invention provide biologically active compounds conjugated or otherwise complexed to the very stable thionin molecule (such as a βME-thionin conjugate), and methods of use of such compounds and/or conjugates for immunostimulation.
REFERENCES:
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4894443 (1990-01-01), Greenfield et al.
patent: 5059413 (1991-10-01), Reardan et al.
patent: 5376640 (1994-12-01), Miyazaki et al.
patent: 5518888 (1996-05-01), Waldman
patent: 5536495 (1996-07-01), Foster
patent: 5547674 (1996-08-01), Khwaja
patent: 5565200 (1996-10-01), Khwaja
patent: 5632983 (1997-05-01), Hadden
patent: 5726156 (1998-03-01), Girten et al.
patent: 5767086 (1998-06-01), Kauvar et al.
patent: 5780037 (1998-07-01), Khwaja
patent: 5804206 (1998-09-01), D'Amelio et al.
patent: 5808140 (1998-09-01), Haridas
patent: 5811452 (1998-09-01), Ojima et al.
patent: 5846548 (1998-12-01), Bartos
patent: 5861483 (1999-01-01), Wolpe
patent: 5885801 (1999-03-01), Rao
patent: 5922902 (1999-07-01), Haridas
patent: 5955432 (1999-09-01), Kauvar et al.
patent: 6003516 (1999-12-01), Hellstrand et al.
patent: 6004558 (1999-12-01), Thurn et al.
patent: 6022535 (2000-02-01), Bauer et al.
patent: 6042848 (2000-03-01), Lawyer et al.
patent: WO 96/41608 (1996-12-01), None
US 5,637,563, 06/1997, Khwaja (withdrawn)
Berzofsky et al., Journal of Clin. Invest. 2004, vol. 113(11):1515-1525.
Angerhofer et al., “Phospholipase activation in the cytotoxic mechanism of thionin purified from nuts ofPyrularia pubera,” Toxicon. 28(5):547-557, 1990.
Baxevanis et al., “Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxic,”Immunopharm. Immunotoxicol. 20(3):355-372, 1998.
Bocci, “Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review,”J. Biol. Reg. Homeo. Agents7(1):1-6, 1993.
Bohlmann et al., “Wounding and chemicals induce expression of the Arabidopsis thaliana gene Thi2.1, encoding a fungal defense thionin, via the octadecanoid pathway,”FEBS Lett. 437(3):281-286, Oct. 23, 1998.
Bussing et al., “Accidental cell death and generation of reactive oxygen intermediates in human lymphocytes induced by thionins from Viscum album L.,”Eur. J. Biochem. 262(1):79-87, May 1999 (abstract only).
Bussing et al., “Expression of mitochondrial Apo2.7 molecules and caspase-3 activiation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing visotoxins,”Cytometry37(2):133-139, Oct. 1, 1999 (abstract only).
Bussing et al., “Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L.”Anticancer Res. 18(6A):4291-4296, Nov.-Dec. 1998.
Büssing et al., “Induction of apoptosis in human lymphocytes treated withViscum albumL. is mediated by the mistletoe lectins,”Cancer Lett. 99:59-72, 1996.
Caaveiro et al., “Interaction of wheat alpha-thionin with large unilamellar vesicles,”Protein Science7(12):2567-2577, Dec. 1998.
Evans and Vernon, “Cellular membrane responses and phospholipase A2activation induced byPyrularia thionin,” J. Nat. Toxins2(2):143-160, 1993.
Evans et al., “Cellular responses toPyrularia thioninare mediated by Ca2+influx and phospholipase A2activation and are inhibited by thionin tyrosine iodination.”Proc. Natl. Acad. Sci. USA86:5849-5853, Aug. 1989.
Evett et al., “Biological properties ofPyrularia thioninprepared from nuts ofPyrularia pubera,” Toxicon. 24(6):622-625, 1986.
Fine et al., “A Specific Stimulator of Granulocyte Colony-Stimulating Factor Accelerates Recovery From Cyclophosphamide-Induced Neutropenia in the Mouse,”Blood90(2):795-802, Jul. 15, 1997.
Fracki et al., “Role of tyr and trp in membrane responses ofPyrularia thionindetermined by optical and nmr spectra following tyr iodination and trp modification,”Toxicon. 30(11):1427-1440, 1992.
Franz et al., “Differences in toxicity and antigenicity between mistletoe lectin I and viscotoxin A 3,”Biomed. Biochim. Acta42(5):K21-K25, 1983.
Froy and Gurevitz, “Membrane potential modulators: a thread of scarlet from plants to humans,”FASEB J. 12(15):1793-1796, Dec. 1998.
Gasanov et al., “In vitro evaluation ofPyrularia thionin—anti-CD5 immunotoxin,”Cancer Immunol. Immunother. 41:122-128, 1995.
Gasanov et al., “ Modification of Phospholipid Membrane Structure by the Plant Toxic PeptidePyrularia thionin,” Arc. Biochem. Biophys. 301(2):367-374, 1993.
Gasanov et al., “Modulation of Phospholipase A2Activity by Membrane-active Peptides on Liposomes of Different Phospholipid Composition,”Gen. Physiol. Biophys. 13:275-286, 1994.
Hamprecht et al., “Mediation of human NK-activity by components in extracts of Viscum album,”Int. J. Immunopharm. 9(2):199-209, 1987 (abstract only).
Huang et al., “Enhancement of adenylate cyclase activity in S49 lymphoma cell membranes by the toxin thionin fromPyrularia pubera,” Toxicon. 32(7):789-797, 1994.
Huang et al., “Interactions of Thionin fromPyrularia puberawith Dipalmitoylphosphatidylglycerol Large Unilamellar Vesicles,”Biochem. 36(10):2860-2866, 1997.
Judd et al., “Pyrularia thioninincreases arachidonate liberation and prolactin and growth hormone release from anterior pituitary cells,” 30(12):1563-1573, 1992.
Jung et al., “Characterization of cytotoxic proteins from mistletoe (Viscum albumL.),”Cancer Lett. 51:103-108, 1990.
Kolusheva et al., “An investigation of the membranotropic properties of the plant toxin thionin isolated fromPyrularia pubera,” Chem. Nat. Comp. 29(4):523-525, 1993.
Kolusheva et al., “Influence of thionin on the structure of a bilayer and on the intermembrane exchange of lipid material,”Chem. Nat. Comp. 30(1):68-72, 1994.
Konopa et al., “Isolation of viscotoxins. Cytotoxic basic polypeptides fromViscum albumL.,”Hoppe Seylers Z. Physiol. Chem. 361(10):1525-1533, Oct. 1980 (abstract only).
Kushmerick et al., “Functional and structural features of gamma-zeathionins, a new class of sodium channel blockers,”FEBS Lett. 440(3):302-306, Dec. 4, 1998.
Kuttan et al., “Effect of a preparation fromViscum albumon tumor development in vitro and in mice,”J. Ethnopharmacol. 29:35-41, 1990.
Kuttan and Kuttan, “Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 6350
Kim Yunsoo
Klarquist & Sparkman, LLP
Szperka Michael
Therapro Technologies, Inc.
LandOfFree
Thionin as an antineoplastic and immunostimulant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thionin as an antineoplastic and immunostimulant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thionin as an antineoplastic and immunostimulant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4112033